Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Thrombosis Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.THROMRES.2006.09.010PMID 17095052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs.

  2006cited by this paper
• Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

  2006cited by this paper
• Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

  2006cited by this paper
• Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX

  2006cited by this paper
• Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.

  2006cited by this paper
• Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.

  2006cited by this paper
• An update on gene therapy for hemophilia.

  2005cited by this paper
• 607. Long-Term Phenotypic Correction of Canine Hemophilia B Following Systemic Administration of Helper Dependent Adenoviral Vector

  2005cited by this paper
• Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

  2005cited by this paper
• Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy

  2005cited by this paper
• Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.

  2005cited by this paper
• Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

  2005cited by this paper
• Sustained Phenotypic Correction of Canine Hemophilia B After Systemic Administration of Helper-Dependent Adenoviral Vector

  2005cited by this paper
• Gene therapy for hemophilia: an imperative to succeed

  2005cited by this paper
• Overview of interleukin-2 function, production and clinical applications.

  2004cited by this paper
• Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy.

  2004cited by this paper
• Development and function of T helper 1 cells.

  2004cited by this paper
• Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer.

  2004cited by this paper
• Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs.

  2004cited by this paper
• Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

  2004cited by this paper
• IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

  2004cited by this paper
• Immune implications of gene therapy for hemophilia.

  2004cited by this paper
• Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

  2003cited by this paper
• Unresponsiveness to Lymphoid-Mediated Signals at the Neonatal Follicular Dendritic Cell Precursor Level Contributes to Delayed Germinal Center Induction and Limitations of Neonatal Antibody Responses to T-Dependent Antigens 1

  2003cited by this paper
• Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.

  2003cited by this paper
• Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

  2003cited by this paper
• The Primary Responses of Murine Neonatal Lymph Node CD4+ Cells are Th2-skewed and are Sufficient for the Development of Th2-biased Memory

  2003cited by this paper
• Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs.

  2002cited by this paper
• Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.

  2002cited by this paper
• Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Immune self-tolerance mechanisms.

  2001cited by this paper
• Lipopolysaccharide potentiates the effect of hepatocyte growth factor upon replication in lung, thyroid, spleen, and colon in rats in vivo.

  2001cited by this paper
• Absence of Circulating Factor IX Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony

  2000cited by this paper
• Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children.

  2000cited by this paper
• Inhibitor Antibodies to Factor VIII and Factor IX: Management

  2000cited by this paper
• Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.

  1999cited by this paper
• Deficient interleukin‐10 production by neonatal T cells does not explain their ineffectiveness at promoting neonatal B cell differentiation

  1998cited by this paper
• Neonatal immunology.

  1998cited by this paper
• Neonatally tolerant rats actively eliminate donor‐specific lymphocytes despite persistent chimerism

  1996cited by this paper
• Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

  1996cited by this paper
• Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells

  1996cited by this paper
• Hematology: Basic Principles and Practice

  1995cited by this paper
• Cytokine regulation of immunoglobulin secretion by neonatal lymphocytes.

  1991cited by this paper
• Canine hemophilia B resulting from a point mutation with unusual consequences.

  1989cited by this paper
• Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation

  1986cited by this paper
• β-Glucuronidase Deficiency in a Dog: a Model of Human Mucopolysaccharidosis VII

  1984cited by this paper
• The cellular mechanism of maintenance of neonatally induced tolerance to H-2 class I antigens.

  1983cited by this paper

• Therapeutic liver cell transplantation to treat a genetic liver defect

  2024cites this paper
• Viral Vector Based Immunotherapy for Peanut Allergy

  2024cites this paper
• Therapeutic liver cell transplantation to treat murine PKU

  2024cites this paper
• Nanotechnology-enabled gene delivery for cancer and other genetic diseases

  2023cites this paper
• Gene therapy for hemophilia: what does the future hold?

  2018cites this paper
• AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

  2018cites this paper
• ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats

  2018cites this paper
• Intrathecal adeno-associated virus vector delivery for mucopolysaccharidosis type I

  2015cites this paper
• Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery

  2015cites this paper
• Biology and Diseases of Cats

  2015cites this paper
• Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.

  2015cites this paper
• Development of gene transfer for induction of antigen-specific tolerance

  2014cites this paper
• Lessons Learned from Animal Models of Inherited Bleeding Disorders.

  2014cites this paper
• Impact of Age at Administration, Lysosomal Storage, and Transgene Regulatory Elements on AAV2/8-Mediated Rat Liver Transduction

  2012cites this paper
• Tissue-and Tumour-Selective Targeting of Murine Leukemia Virus-Based Replication-Competent Retroviral Vectors

  2012cites this paper
• Animal models of hemophilia.

  2012cites this paper
• Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications.

  2011cites this paper
• Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

  2011cites this paper
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

  2011cites this paper
• Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism

  2011cites this paper
• A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

  2011cites this paper
• Retroviral vector-mediated gene therapy for metabolic diseases: an update.

  2011cites this paper
• O USO DE CÉLULAS-TRONCO MESENQUIMAIS COMO NOVA PERSPECTIVA DE TRATAMENTO PARA HEMOFILIA B THE USE OF MESENCHYMAL STEM CELLS AS A NEW PERSPECTIVE OF TREATMENT FOR HEMOPHILIA B

  2011cites this paper
• Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia?

  2011cites this paper
• Special lectures in haemophilia management

  2010cites this paper
• Clinical and molecular characterization of a re‐established line of sheep exhibiting hemophilia A

  2010cites this paper
• Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

  2009cites this paper
• Prenatal gene therapy for the early treatment of genetic disorders

  2009cites this paper
• Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

  2009cites this paper
• Hepatic gene transfer as a means of tolerance induction to transgene products.

  2009cites this paper
• Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.

  2009cites this paper
• A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.

  2009cites this paper
• Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

  2009cites this paper
• The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer.

  2009cites this paper
• In vivo models of haemophilia – status on current knowledge of clinical phenotypes and therapeutic interventions

  2008cites this paper
• 1 THE IMMUNOLOGY OF GENE TRANSFER : AN OVERVIEW

  2008cites this paper
• Factor IX: Insights from knock-out and genetically engineered mice

  2008cites this paper
• Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.

  2007cites this paper
• A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice.

  2007cites this paper
• Immunology of neonatal gene transfer.

  2007cites this paper
• High expression reduces an antibody response after neonatal gene therapy with B domain‐deleted human factor VIII in mice

  2007influential citation